At the annual meeting of the American Society of Clinical Oncology held in Chicago, researchers from the Mayo Clinic reported results from a Phase II trial which provide additional evidence of clinical activity and low toxicity for epigallocatechin gallate (EGCG, extracted from green tea) in chronic lymphocytic leukemia (CLL) patients.* Hematologist Tait Shanafelt, MD and colleagues gave 2,000 milligrams EGCG to patients with early stage, asymptomatic CLL.